Cookie-Settings

Here you can see and modify the cookie settings of various tools used on www.advantageaustria.org and related subdomains.


Save settings
Advantage Austria Show navigation

Austrian Biotech Company “APEIRON” Announces Start of its First Clinical Trial for Neuroblastoma Patients in Japan

11.07.2014

Japan a New Hotspot for International Pharma and Biotech Research?  

Tokyo, Vienna, July 8th, 2014: Austrian biotech company APEIRON Biologics AG (“Apeiron”) announced today that a phase I clinical trial with its neuroblastoma immunotherapy APN311 has received all necessary approvals to start recruiting patients.
The trial will be locally conducted by Nagoya University Hospital and is part of a long-term collaboration to make this therapy available to patients suffering from this severe type of children’s cancer. In Japan, it won a grant by the Japanese government as an Investigator-initiated clinical trial that utilizes collaboration between the Department of Pediatrics and the Center for Advanced Medicine and Clinical Research (CAMCR) at Nagoya University Hospital.

Press Release: Austrian Biotech Company “APEIRON” Announces Start of its First Clinical Trial for Neuroblastoma Patients in Japan [pdf, 249.4kb]

print
©©ADVANTAGE AUSTRIA